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Background/aim: We aimed to reveal the incidence and predictive role of insulin resistance and distorted oral glucose tolerance test in
nondiabetic patients with Bell’s Palsy (BP).
Materials and methods: Eighty-six patients with BP and 28 control subjects; all with normal blood glucose levels and no history of
diabetes, were enrolled in the study. We investigated insulin resistance (IR) in all subjects, in terms of HOMA-IR greater than 2.7. Sixtytwo of the patients also underwent an oral glucose tolerance test (OGTT).
Results: The mean HOMA-IR value was significantly increased in patients, compared to the control group (3.2 vs 1.6; P < 0.01). IR was
detected more in BP patients than in controls (P < 0.05). The patients with higher HOMA-IR values had more severe facial dysfunction
at the initial presentation and complete recovery time took longer than the patients with normal HOMA-IR value (75 days vs 42 days; P
< 0.05). Following a 2h-OGTT, impaired glucose tolerance and newly diagnosed DM were found in 60% of the patients. Recovery time
was significantly longer in prediabetics and newly diagnosed diabetic patients than in patients with normal glycemia (68 days, 52 days,
and 32 days, respectively; P < 0.01).
Conclusion: There is a strong linkage between HOMA-IR value and BP prognosis so HOMA-IR value may have a significant role of
predicting BP prognosis at presentation.
Key words: Bell’s palsy, insulin resistance, prediabetes, HOMA-IR index

1. Introduction
Facial mimetic muscles are a group of striated skeletal
muscles innervated by the facial nerve (FN) with a
complex range of functions including the expression of
the emotional status involuntarily. FN is also composed
of parasympathetic to the lacrimal, submandibular and
sublingual glands; sensory innervation to the part of the
external ear and contribution to taste at the anterior two
thirds of tongue [1]. Due to its complex and bony covered
anatomical course, FN is the most prone nerve to ischemic
and inflammatory injuries among the all cranial nerves [2].
The ancients suffered so much from facial paralysis than
any other types of cranial neuropathies that it has become
one of the most significant clinical problems throughout

history even in the riddle of Leonardo da Vinci’s ‘Mona
Lisa’ [3]. Facial paralysis has a broad range of possible
aetiologies including numerous acquired and some
congenital causes. Bell’s palsy (BP), defined as idiopathic
facial paralysis, is the most frequent type with an incidence
of 20/100.000 in the Western adult population [4].
There is no identified cause of BP, but some possible
aetiologies include viral inflammation and/or microvascular problems. The prognosis for individuals with
BP is generally very good, but diabetes associated
microangiopathy may be a potential etiologic and poor
prognostic factor in BP [5]. Microcirculatory failure
of the vasa nervosum impairs nerve metabolism and
causes venous stasis, resulting in accumulation of toxic
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metabolites accompanied by a cascade of oedema and
ischemia [6].
On the other hand, neuropathy is the most common
chronic complication of diabetes mellitus. There are 3
types of diabetic neuropathy: autonomic neuropathy,
peripheral neuropathy, mononeuropathy [7]. Metabolic
factors play role in autonomic and peripheral neuropathy,
whereas involvement of vasa nervorum leads to the
mononeuropathy [7]. Subclinical facial nerve dysfunctions
were detected in 70% of patients with diabetic
polyneuropathy [8]. Early stages of hyperglycaemia even
cause distal peripheral nerve damage [8]. Impaired glucose
tolerance (IGT) was observed in 45% of 187 patients with
idiopathic neuropathies [9].
Neuropathic pain is one of the most common symptoms
of IGT [10]. Prevalence of glucose metabolism disorders
and insulin resistance were found higher in nondiabetic
patients with BP than control group [11].
Prediabetes, defined as impaired fasting glycemia
(IFG) and IGT associated with insulin resistance (IR), have
an increased risk of developing diabetes [12]. Mechanisms
underlying the pathogenesis of diabetic or even prediabetic
neuropathy is associated with IR leading to neuronal
injury via neuronal insensitivity to neurotropic properties
of insulin [13].
In this clinical study; we evaluated HOMA-IR, and
prediabetic status with an oral glucose tolerance test
(OGTT) in nondiabetic patients with BP. Our purpose
was to reveal the clinical relationship between BP and IR/
prediabetes. We also assessed the effect of higher HOMAIR value and prediabetes status on the prognosis and
recovery period of BP.
2. Materials and methods
The study was approved by the Ethical Committee of
Ministry of Health, Dışkapı Training and Research
Hospital on March 2014 (all patients and people in
control group gave their consent and informed consent
was obtained and signed by each, in accordance with the
official standards of the Declaration of Helsinki (1964),
local laws and regulations). The registration number was
14/34.
Between March 2014 and March 2015, we studied
prospectively 86 nondiabetic patients with Bell’s palsy (40
women and 46 men) and 28 nondiabetic control subjects
(18 women and 10 men) without a history of facial nerve
palsy. All the subjects had normal blood glucose levels
(fasting level < 100 gr/dL).
All the patients and the controls underwent the
following tests: pure tone audiogram, stapes reflex, blood
chemistry screen (including Vit B12, folic acid, serum
HbA1c, cholesterol, triglyceride, iron and uric acid levels),
temporal bone magnetic resonance imaging (MRI).
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According to the World Health Organization
classification, a body mass index (BMI) over 25 kg/m2 was
defined as overweight, and over 30 kg/m2 as obese [14].
Exclusion criteria included the followings; previous
otologic disease history and surgery, hereditary hearing
loss, congenital facial paralysis, pregnancy, autoimmune
rheumatic diseases, head trauma, history of alcohol abuse,
chronic liver/kidney disease, the use of medications
that affect glucose metabolism (such as beta-blockers,
corticosteroids).
The House-Brackmann (HB) scale was used to quantify
and describe facial nerve dysfunction.
To find a more accurate prognostic factor as well as
to yield an estimate of insulin resistance in nondiabetic
falsy palsy patients we measured the HOMA-IR measured
by fasting blood glucose and insulin levels in 86 patients
before starting steroid treatment. HOMA-IR used for
evaluation of insulin sensitivity was calculated by the
formula; basal plasma glucose (mg⁄dL) × basal plasma
insulin (UI ⁄mL) ⁄ 405. HOMA-IR over 2.7 was admitted as
abnormal according to the study of Bosco et al. and a study
of Turkish population [11,15]. Written informed consent
was obtained from 62 of 86 patients before performing
OGTT. A zero time (fasting) venous blood sample was
drawn after 10 h of overnight fast. The patients were
then given a 75 g oral glucose load within a 5 min time
frame. Venous blood was drawn after an interval of 2 h
for measurement of glucose [16]. Systemic administration
of corticosteroids was used for treatment of BP patients
as soon as OGTT was performed and HOMA-IR was
calculated. The standard treatment regimen consisted of
initial administration of intravenous methylprednisolone
250 mg. On day 2, patients received oral Metilprednizolon
1 mg/kg/day. The corticosteroid dose was tapered 20 mg
every second day until termination.
3. Results
This study included 86 nondiabetic patients with BP; 40
were females (46%) and 46 were males (54%) and their
ages ranged from 18 to 75 years with a mean of 41. Of the
28 control subjects; 18 were females (65%) and 10 were
males (35%) and their ages ranged from 18 to 70 years,
with a mean age of 38. None of the controls had a history
of diabetes and BP. No significant difference was found in
age and sex between 2 groups (P > 0.05) (post hoc test).
Mean BMI of 86 patients was found as 28 kg/m2; they
were divided into 2 groups 17 patients had normal weight
(BMI < 25), and 67 patients were overweight and obese.
The mean BMI of the control group was 27.3 kg/m2; BMI
less than 25 kg/m2 was found in 7 subjects while BMI ≥
25 kg/m2 was observed in 21 subjects. No significant
difference was found between BMI distributions of the 2
groups (P > 0.05) (t test).
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Four of 86 patients already had hypertension; but
others had no history of systemic disease. Similarly, 2
of 28 control subjects had hypertension. The mean time
between disease onset and diagnosis was 1.8 day (min 1
day, max 10 days; 80 of 86 patients applied within 3 days
of clinical onset). BP affected the left side in 59% of the
patients. Twelve patients suffered from previous episodes
of unilateral facial nerve paralysis; 74 patients had their
first attack.
Most of the patients suffered from incomplete facial
palsy at the initial diagnosis (Table 1).
The mean value of HOMA-IR in patients’ group
was found as 3.2 and was higher than the mean value of
HOMA-IR in the control group which was calculated as
1.6.
Therefore, the mean HOMA-IR of the patients were
significantly higher than the controls (P < 0.001) (Mann–
Whitney test).
Of the 86 patients; 48 (55.8%) had HOMA-IR of <2.7;
and 38 (44.2%) had HOMA-IR of ≥2.7; and of the 28
control subjects 23 (82%) had HOMA-IR of <2.7; and 5
(18%) had HOMA-IR of ≥2.7 (P < 0.05) (Pearson chisquare test) (Table 2). The percentage of high HOMA-IR
subjects were higher in the BP group when compared to
the controls.
Average value of HbA1c in patients’ group was found
as 5.6 and 5.4 in the control group, the difference was not
significant (P > 0.05).
OGTT could be performed in 62 of the patients and
following the 2 h-OGTT, we found an abnormal glucose
metabolism in 37 patients (29 patients with IGT and 8
patients with new onset DM).
We could determine the exact recovery time of 56/86
patients. Recovery time of patients with HOMA-IR value
of ≥2.7 was significantly longer than patients with HOMAIR value of <2.7 (75.8 days and 42.9 days, respectively; P
< 0.048; Mann–Whitney U) Recovery time, with respect
to OGTT, was statistically longer in prediabetic and newly
diagnosed diabetic patients than in patients with normal
glycaemia (68 days, 52, days and 32 days, respectively, P
< 0.01).
When we looked at the relationship between HOMAIR and HB stage at the initial patient presentation; the
group with lower HOMA-IR value had statistically more
patients with HB grade 2 and 3. Additionally 18 of the 30
patients with HB grade 4,5, and 6 were detected in the
higher HOMA-IR group (P < 0.05; Pearson chi-square)
(Table 3).
4. Discussion
Bell’s palsy as an acute impairment of facial nerve
functions, is a diagnosis of exclusion and affects men
and women equally. The peak incidence is between the
ages of 15–45, but may occur at any age [2]. There is no

Table 1. Distribution of clinical severity of 86 patients with facial
palsy at the initial diagnosis.
House Brackmann grading scale

n = 86
Count (%)

2

35 (41.4%)

3

21 (24.1%)

4

16 (18.4%)

5

6 (6.9%)

6

8 (9.2%)

known blood test to give the diagnosis of BP or to predict
the prognosis. There is also no proved etiologic factor or
disease in BP. Viral infections and diabetes are considered
to have some role in the etiopathogenesis and prognosis
of BP. Our hypothesis in the present clinical study was;
IR or prediabetes may play a role in the clinical severity
and prognosis of the disease in nondiabetic BP patients.
Therefore, we included the BP patients with normal fasting
blood glucose levels (<100 gr/dL) in this study. All our
patients were given steroids but no antiviral agents, all our
patients recovered to at least HB grade 2 with different
recovery periods, none of our patients underwent surgery
for facial nerve decompression. In our study considering
the optimal HOMA-IR cut off value as 2.7 for Turkish
population, 45% of BP patients presented with higher
HOMA-IR levels, as well as the 18% of the controls. In
addition to that, the mean value of HOMA-IR was 3.2 in
the patients’ group, whereas it was 1.6 in the control group.
Our results are consistent with the hypothesis that insulin
resistance is more frequent in nondiabetic BP patients.
These data may point out to a role for insulin resistance in
the etiopathogenesis of BP as well.
The mean age of the patients in our study was 41,
parallel to that of the literature. While 30% of BP cases
reported in the literature suffer from partial paralysis at the
onset, 85% of our patients suffered from partial paralysis
(House Brackman grade 2-3-4). In our study, in the lower
HOMA-IR group (<2.7) there were less patients presenting
with severe HB grades (5–6) but more with lower HB
grades (2–3–4). There were totally 14 patients presenting
with HB grade 5 and 6 in the study, and of these patients
10 had HOMA-IRof >2.7. Our findings suggest that, those
BP patients with higher HB grades had higher HOMAIR. Therefore it is possible to comment that prediabetic
status or IR can be associated with worse HB grade at
presentation. This result may also be consistent with the
hypothesis that IR can have a role in the etiopathogenesis
of BP.
Based on the OGTT in 62 of the BP patients, prevalence
of glucose metabolism abnormalities was found in 60%
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Table 2. Distribution of patients and control groups in terms of
their HOMA-IR index with cut off value of 2.7.

Table 3. Relationship between HOMA-IR and HB stage at
presentation.

Number of patients

Number of patients

HOMA-IR HOMA-IR Total
value of <2.7 value of ≥2.7
Bell’s palsy patients 48 (55.8%)
38 (44.2%)
86 (100.0%)
Groups

Control

23 (82.1%)

5 (17.9%)

28 (100.0%)

P: 0.023

House Brackman
grading scale

HOMA-IR
value of <2.7

HOMA-IR
value of ≥2.7

2

26 (74.3%)

9 (25.7%)

3

10 (47.6%)

11 (52.4%)

4-5-6

12 (40%)

18 (60%)

P = 0.015 (chi-square test)

of our patients (47% with IGT and IFG and 13% with
a newly diagnosed DM). BMI over 25 kg/m2 was found
in 77% of patients and 75% of control group. This data
emphasizes that HOMA-IR value and/or impaired
OGTT, rather than BMI may play role in BP. Our study
may have some criticisms. Firstly the 2h-OGTT was not
performed after loading the diet with carbohydrates for
4 days, this is because we should start steroid treatment
as soon as possible and secondly, we could not perform
OGTT to control group because it was time consuming,
costly, and risky attempt.
BP is considered to be a consequence of entrapment
neuropathy following inflammation, oedema and
strangulation due to microangiopathies, which responds
to corticosteroids significantly [6,17]. Unlike other cranial
nerves, facial nerve with its long bony canal is open to
effects of inflammation and oedema and presents with
various degrees of nerve damage. Perineural vascular
congestion gives rise to nerve injury determined on
MRI and detected perioperatively while improvement
was also shown after steroid treatment [17,18,19].
Considering that DM is frequent in BP patients, Adour
et al. advised screening for blood sugar elevation for
those, who have recurrent facial paralysis [20]. On the
other hand, Schwann cells and the myelin sheath are
more likely to be affected in diabetics than nondiabetic
patients [20]. The early stages of hyperglycaemia are
critical for peripheral nerve damage which may result
in peripheral neuropathy [8,9]. Prediabetic neuropathy
affects sensory nerve fibres particularly more than motor
nerve fibres [21].
Osmosis in early stages of hyperglycaemia directly
causes myelin sheath damage in small nerve fibres [22].
Therefore, prediabetic neuropathy is an indicative of
early distal small sensory neuropathy whereas diabetic
neuropathy causes loss of vibration sense [23].
Even though some studies could bring a conclusion
that DM or hyperglycaemia itself does not cause facial
nerve palsy but may facilitate the demyelination and
degeneration of the facial nerve during HSV-1 infection
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[24]. This may end with facial nerve paralysis, and
histopathologically confirmed that HSV-1 infection and
nerve degeneration were more remarkable in the DM
mice than in non-DM mice [24].
Sittel et al. reported no significant differences in
complete recovery rate from BP, between diabetic and
nondiabetic groups [25]. The underlying reason for
that may be the possible presence of prediabetic and
IR patients in nondiabetic group. In our study, all our
patients recovered to at least HB grade 2 regardless
of the prediabetic status or IR. However, our patients
with HOMA-IR of >2.7 had longer recovery time
compared to those with HOMA-IR of <2.7 (76 days vs
43 days, respectively). Although there was no apparent
hyperglycaemia, higher HOMA-IR had some role in
the recovery period time. It seems that neuropathy in
BP is not only correlated to hyperglycaemia associated
pathogenesis. Prediabetic neuropathy has been delineated
by multiple potential pathogenical mechanisms. Leading
to oxidative stress in addition to activation of protein
kinase C (PKC) and polyol pathway, hyperglycaemia
has neurotoxic effect directly [26]. In an animal study,
hyperglycaemia induces apoptotic changes in dorsal
root ganglion neurons and Schwann cells which result in
damaged mitochondria in the nerve fibre and premature
neuronal death [26,27,28]. In vivo acute transient
hyperglycaemia episodes lead to endothelial dysfunction
due to increase of reactive oxygen metabolites. This may
result in neuronal metabolic dysfunction and consequent
direct DNA damage which promote neuronal cell death
[29]. In diabetic patient’s chronic hyperinsulinemia
may cause reduction in endoneural oxygen, reduced
blood flow, and epineurial arteriovenous shunting and a
compensatory response to endoneural ischemia/hypoxia;
and these may all contribute to chronic nerve ischemia
[6].
The relationship between facial palsy and DM is well
known. However, there are few controlled studies on the
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association of facial palsy and manifestation of prediabetes
and insulin resistance. The most widely accepted
prognostic indicator of BP is electroneuronography
(ENoG) test, however we believe that calculating HOMAIR value may also give additional clues to predict the
prognosis. In a clinical study it was stated that; although
being diabetic does not influence the severity of facial
palsy at the time of onset, recovery time from Bell’s
palsy took longer in patients with diabetes compared to
the nondiabetic patients [30]. Our data suggested that
patients with higher HOMA-IR presented with higher
HB grade and they recovered later than the lower HOMAIR patients. Hyperglycaemia induces direct nerve injury
by similar pathogenetic mechanisms either in IGT or in
diabetes [21]. Glycaemic control is a crucial factor in the
progress of neuropathy [31]. Therefore, targeted therapy
in BP may also include regulation of glucose metabolism
even in nondiabetic patients with IR.
Our clinical data documented that there may be a
linkage between facial palsy and insulin resistance, in
terms of severity and prognosis in Bell’s palsy. We found
that in nondiabetic patients with BP; those with higher
HOMA IR of >2.7 and prediabetics had longer recovery
period. Therefore, further studies in larger groups are

needed in understanding the underlying potential
mechanisms of insulin resistance and distorted OGTT.
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